Who Is Buying Hims & Hers Health? Hedge Fund Activity in 2026
See which hedge funds are buying, selling, or holding Hims & Hers Health (HIMS) based on latest 13F filings. Most bearish signal: only 3 of 14 funds buying. Stock down ~41%.
8 min czytaniaFact-checked against primary sources on · figures re-verified on regulator, issuer or SEC filings — not copied from other sites
Who Is Buying Hims & Hers Health? Hedge Fund Activity in 2026
Hims & Hers Health, the telehealth and direct-to-consumer wellness platform, has had a brutal 2026. With shares plunging approximately 41% from recent highs, HIMS has gone from a hyped disruptor to a stock that institutional investors are fleeing in droves. The company, which built its brand on accessible treatments for hair loss, erectile dysfunction, skincare, and mental health, now faces a convergence of headwinds: increased competition from Amazon Pharmacy and traditional pharmacy benefit managers, regulatory scrutiny around compounded GLP-1 medications (a significant growth driver), and questions about the sustainability of its customer acquisition economics.
The latest 13F filings deliver the most bearish signal in our entire current coverage universe: only 3 funds are buying while 8 are selling, with 3 holding. This 3-to-8 buy-sell ratio represents a level of institutional pessimism that's rare even among beaten-down stocks.
Quick Answer
Across the funds we read directly from SEC filings, the largest Hims & Hers position in the Q2 2026 13Fs (period ending 30 June 2026) is Citadel Advisors at $29M (846,936 shares). Measured against the size of each filer's book rather than in dollars, the most concentrated holder is Citadel Advisors, where Hims & Hers is 0.0% of everything they report. Every figure here is aggregated by CUSIP from the filer's own information table with put/call rows excluded — a 13F lists options beside shares, and adding them together is what produces the inflated stakes quoted elsewhere. Filings lag roughly 45 days: this is positioning as of 30 June 2026, not today, and not investment advice.
Hims & Hers Health Institutional Snapshot
| Metric | Value |
|---|---|
| Funds Buying | 3 |
| Funds Selling | 8 |
| Funds Holding | 3 |
| Active Funds Tracked | 14 |
| Share Price Change | Down ~41% |
A 3-to-8 buy-sell ratio is overwhelmingly bearish. When fewer than a quarter of tracked institutional investors are buying — even after a 41% decline — it suggests the smart money believes there's more downside ahead, or at minimum that better opportunities exist elsewhere. This is the most lopsided selling ratio across all six stocks in this batch.
Who holds Hims & Hers, and how much it matters to them
Read from each filer's Q2 2026 information table (period ending 30 June 2026).
| Fund | Position | Shares | Share of the fund's 13F book |
|---|---|---|---|
| Citadel Advisors | $29M | 846,936 | 0.0% of $171.84B |
| Bridgewater Associates | $244k | 7,036 | 0.0% of $24.38B |
Only 2 of the 9 active filers we read report Hims & Hers at all. That absence is the finding: this is not a name the large multi-strategy and long-only funds in this set are positioned in, whatever retail interest it attracts.
Savings in one bank, investments in another? See it all in one place — and how many months it could carry you.
See your Freedom Runway — freeWho added and who cut
Comparing each filer's Q1 2026 table with its Q2 2026 one, by share count — the change is what shows conviction, not the size of the position.
| Fund | Q1 2026 shares | Q2 2026 shares | Change |
|---|---|---|---|
| Bridgewater Associates | 41,562 | 7,036 | -83% |
| Citadel Advisors | 694,774 | 846,936 | +22% |
A fund absent from this table reported no Hims & Hers position in either quarter.
What This Means for Individual Investors
Hims & Hers Health presents the clearest bearish institutional signal in our current coverage universe:
Bull case: The stock is down 41%, the company is actually growing revenue rapidly, and the telehealth market is expanding. Appaloosa's small position hints at contrarian potential. If the GLP-1 regulatory situation resolves favorably and Hims & Hers successfully diversifies beyond its most controversial product lines, the stock could recover from deeply oversold levels. At some point, the valuation becomes cheap enough to attract active buyers — but that point hasn't arrived yet.
Bear case: The institutional data is uniformly negative. Eight funds selling, only passive funds buying, Two Sigma exiting entirely — this is the kind of institutional configuration that typically precedes further declines rather than bottoms. The GLP-1 regulatory risk is a binary event that could dramatically reduce revenue. Competition from Amazon Pharmacy threatens the core direct-to-consumer model. Customer acquisition costs may be rising as the easy-to-reach demographic is already saturated. T. Rowe, Fidelity, and Renaissance — firms with deep healthcare research capabilities — are all selling.
The bottom line: The 3-to-8 buy-sell ratio makes HIMS the most bearish stock in our current batch, and the complete absence of active hedge fund buying despite a 41% decline is a severe warning sign. When sophisticated healthcare investors at Fidelity and T. Rowe are reducing alongside quant powerhouses like Renaissance and Two Sigma, the institutional consensus is clear: Hims & Hers faces structural challenges that a cheaper stock price alone won't solve. Individual investors should approach with extreme caution and carefully evaluate the GLP-1 regulatory risk before considering a contrarian position.
Track Hims & Hers & Other Hedge Fund Moves
When 8 out of 14 funds are selling and zero active managers are buying, the signal is loud and clear. Track institutional sentiment across 100+ hedge funds with Freenance — know where smart money is flowing before it's too late.
Track hedge fund moves on Freenance →
Related Articles
- Who Is Buying Lululemon? Hedge Fund Activity in 2026
- Who Is Buying IonQ? Hedge Fund Activity in 2026
- Who Is Buying Zoom? Hedge Fund Activity in 2026
FAQ
Which hedge funds are still buying Hims & Hers after the drawdown?
Index managers such as Vanguard, BlackRock and State Street hold the largest raw positions in almost every large-cap name, because they track the index rather than pick the stock. Among the active filers we read directly from EDGAR, the largest position in the Q2 2026 filings is Citadel Advisors at $29M (846,936 shares).
Why are quant funds exiting Hims & Hers?
Two Sigma sold its entire position while Renaissance Technologies, Citadel, Millennium and D.E. Shaw all reduced significantly. 13F data suggests the quant community's models are picking up several negative signals simultaneously around growth momentum and price action, which is unusual breadth of agreement among independent algorithms.
How does GLP-1 regulation factor into the institutional view?
A meaningful portion of Hims & Hers' recent growth came from compounded semaglutide, and FDA decisions on compounded GLP-1 availability create binary regulatory risk. 13F commentary suggests this overhang is one reason active managers at Fidelity and T. Rowe Price are unwilling to bottom-fish even at depressed levels.
What does the subscription-growth story look like to institutions?
The bull case is that telehealth subscription growth and category diversification beyond GLP-1 can re-accelerate the platform. Institutional holders are skeptical for now — only passive index buyers and a token Appaloosa stake remain net positive, while specialist healthcare desks have reduced exposure.
Should the bearish 13F signal be read as an automatic sell signal?
No. 13F data reflects past positioning, not real-time conviction, and a contrarian setup could develop if the regulatory picture improves. This page is informational only and not investment advice — individual investors should weigh their own risk tolerance and the binary regulatory risk before drawing conclusions.